Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer (Q46218492)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9848583

Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9848583

phase II clinical trial

0 references

author name string

Edelman MJ

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9848583

Meyers FJ

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9848583

Grennan T

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9848583

Lauder J

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9848583

Doroshow J

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9848583

publication date

1 January 1998

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9848583

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9848583

16

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9848583

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9848583

179-182

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9848583

Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).

1 reference

https://pubmed.ncbi.nlm.nih.gov/9848583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9848583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9848583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9848583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/9848583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy in advanced prostate cancer: a silk purse?

1 reference

https://pubmed.ncbi.nlm.nih.gov/9848583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9848583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9848583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9848583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9848583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro cytotoxicity of pyrazine-2-diazohydroxide: specificity for hypoxic cells and effects of microsomal coincubation

1 reference

https://pubmed.ncbi.nlm.nih.gov/9848583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 1997.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9848583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/9848583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/A:1006097109088

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9848583

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9848583

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46218492&oldid=2207723966"